Identification and Enhancement of HLA-A2.1-Restricted CTL Epitopes in a New Human Cancer Antigen-POTE

Modification of One Epitope-Flanking Amino Acid Allows for the Induction of Friend Retrovirus-Specific CD8+ T Cells by Adenovirus-Based Immunization

(2012) P. Godel et al.   JOURNAL OF VIROLOGY

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

(2012) Steffen Walter et al.   NATURE MEDICINE

Harmonizing the immune response with a cancer vaccine

(2012) Lisa Hutchinson   Nature Reviews Clinical Oncology

Strategies to Use Immune Modulators in Therapeutic Vaccines Against Cancer

(2012) Jay A. Berzofsky et al.   SEMINARS IN ONCOLOGY

Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4+ T-cell repertoire selection

(2012) David K. Cole et al.   Nature Communications

Overview of the cancer vaccine field

(2012) Alex Kudrin et al.   Human Vaccines & Immunotherapeutics

PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine

(2011) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Provenge: combating prostate cancer with a vengeance?

(2011) Thomas Schwaab et al.   Expert Review of Vaccines

HLA-A*0201-restricted CEA-derived Peptide CAP1 Is Not a Suitable Target for T-cell-based Immunotherapy

(2010) Emilie Fauquembergue et al.   JOURNAL OF IMMUNOTHERAPY

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Generation of cytotoxicity against hepatitis delta virus genotypes and quasispecies by epitope modification

(2009) Yi-Hsiang Huang et al.   JOURNAL OF HEPATOLOGY

Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen

(2008) D. E. Speiser et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA